Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00964366
First received: August 20, 2009
Last updated: March 6, 2012
Last verified: March 2012

August 20, 2009
March 6, 2012
July 2009
August 2009   (final data collection date for primary outcome measure)
  • Skin Erythema (Redness) [ Time Frame: 2 Weeks ] [ Designated as safety issue: No ]

    Assessment of erythema as part of an evaluation of tolerance of two treatments: clindamycin and benzoyl peroxide or dapsone gel. This was done by visual assessment by an independent blinded grader using the grading scale shown below.

    Grade Description 0 None 2 Mild erythema 4 Moderate confluent erythema 6 Marked erythema with some edema 8 Marked erythema, edema, possible erosion

  • Skin Dryness [ Time Frame: Baseline, Day 1through Day 14 ] [ Designated as safety issue: No ]

    The amount of dryness on the left and right cheek of each panelist.

    The scale used to evaluate skin dryness is:

    Grade Description 0 None 2 Slight flaking 4 Moderate flaking/scaling 6 Marked scaling / slight fissuring 8 Severe scaling, fissuring

    Expert Grader assessments of dryness were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

To determine and compare the tolerance and irritation potential of clindamycin and benzoyl peroxide to dapsone gel using visual assessments by an independent blinded grader. [ Time Frame: 2 Weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00964366 on ClinicalTrials.gov Archive Site
  • Transepidermal Water Loss (TEWL) [ Time Frame: 2 Weeks ] [ Designated as safety issue: No ]
    To assess skin moisture and hydration using transepidermal water loss (TEWL). These tables record the data obtained for each panelist at Baseline, and on Days 3, 7 and 14 or upon early termination of site(s), if applicable. Results are measured on a continuous scale.
  • Sebum Measurements [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
    To sample the skin surface, the sebum collector strips are applied to the skin sites for 10 seconds. Once removed, these samples will be immediately measured for the amount of sebum on the strip using the tape analyzer. The amount of sebum production was measured as the amount of sebum collected on a tape applied to the skin for 10 seconds and then converted to 1 of 10 incremental levels. Sebum production was measured in increments of 0 (minimum value) to 10 (maximum value). The higher the number, the greater amount of sebum produced.
  • Skin Hydration [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
    Evaluation of Skin Hydration using electrical conductance measurements,on weekdays during 14 days of treatment. The value recorded which is expressed in units of microsiemens represents the AC conductance 2-3 seconds after placing the spring-loaded probe tip to the sample site.
To assess skin moisture and hydration using transepidermal water loss (TEWL), sebum measurements and electrical conductance measurements, and to assess subject tolerability and Preference. [ Time Frame: 2 Weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications
Two-week Study to Determine and Compare the Tolerance and Irritation Potential of Clindamycin and Benzoyl Peroxide to Dapsone Gel Topical Acne Medications

This is a randomized, half-face study. On 1 side of the face, the subject will apply 1 of the 2 test products, clindamycin and benzoyl peroxide or dapsone gel and the contra lateral side of the face will remain non-treated to serve as a control.

This is a single-blind (blinded expert grader), parallel group, randomized, half-face study being conducted at one clinical site. On 1 side of the face, the subject will apply 1 of the 2 test products, clindamycin and benzoyl peroxide or dapsone gel and the contra lateral side of the face will remain non-treated to serve as a control. Approximately 25-30 male and female healthy subjects without facial acne, aged 18 to 45, will be randomly assigned to each product.

The eligible subjects who qualify will be entered into a 2-week treatment phase. The first of application of the study medication will be supervised at the site, Monday through Friday of each week. Any additional applications should be applied by the subjects at home each evening and the times of application recorded on a diary card. Subjects will apply the study product at home on Saturdays and Sundays and record the times of application on a diary card.

A blinded expert grader will rate comparative product tolerance during the study before study product is applied.

Instrumentation measurements of TEWL will be utilized to evaluate product mildness.

Duplicate sebum samples will be taken from the left and right forehead areas and assessed.

Subject will complete questionnaires and all adverse events will be recorded.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Acne Vulgaris
  • Drug: clindamycin and benzoyl peroxide
    Daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide
    Other Name: Duac® gel
  • Drug: Dapsone gel
    Twice-daily applications of dapsone gel
    Other Names:
    • ACZONE® (dapsone) Gel
    • 5%
  • Experimental: Clindamycin/BPO gel
    Once-daily applications of clindamycin/BPO gel to the randomized side of the face either left or right.
    Intervention: Drug: clindamycin and benzoyl peroxide
  • Active Comparator: Dapsone gel
    Twice-daily applications of dapsone gel to one side of the face.
    Intervention: Drug: Dapsone gel
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
53
August 2009
August 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Capable of understanding and willing to provide signed and dated written voluntary informed consent (and any local or national authorization requirements) before any protocol specific procedures are performed.
  • Male and female subjects aged from 18 to 45 years at time of consent.
  • Has a Fitzpatrick Skin Type of I, II, or III.
  • Is willing to discontinue use of all facial products (other than the cleanser provided and makeup or razor and facial shave product) on the face for the 3 days before their baseline/day 0 visit and use only the provided facial products and their normal makeup or razor and facial shaving product for the duration of the study.
  • Is willing to not change brands of makeup or razor and facial shave product during the study.
  • Is willing to refrain from using any facial product on the face other than study products and their normal makeup or razor and facial shave product for the duration of the study.
  • Is willing to refrain from exercising prior to their instrument appointments.
  • Is willing to refrain from showering or drinking caffeinated beverages within 1 hour prior to their instrument visits.
  • Is willing to report to the site for each visit with a clean face and no makeup.
  • Is willing to avoid sunburn, tanning, tanning beds or other excessive sun exposure. Understands that if their skin tone changes significantly during the study it will be necessary to discontinue their participation.
  • Able to complete the study and to comply with study instructions.
  • Sexually active females of childbearing potential participating in the study must agree to use a medically acceptable method of contraception while receiving protocol-assigned product. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant; including perimenopausal women who are less than 2 years from their last menses.

Exclusion Criteria:

  • Female subjects who are pregnant, trying to become pregnant, or breast feeding.
  • Male subjects that have facial beards (mustache and/or goatee is acceptable).
  • Is a Type I diabetic.
  • Has active or chronic skin allergies.
  • Has a history of acute or chronic disease that might interfere with, or increase the risk of study participation.
  • Has participated in other facial studies in the preceding 30 days or other clinical studies in preceding 14 days.
  • Had skin cancer treatment in preceding 12 months.
  • Has damaged skin on facial areas (eg, from sunburn, tattoos, scars).
  • Had any medical procedure (e.g., laser resurfacing, chemical peels, plastic surgery) to facial areas in preceding 12 months.
  • Had any cosmetic procedure (e.g., microdermabrasion, etc.) to facial areas within 8 weeks of the baseline visit.
  • Use of topical retinoids or related agents for the treatment of acne or photoaging in the preceding 6 months.
  • Live in the same household as currently enrolled subjects.
  • Employees of investigator/clinical research organization (CRO) or Stiefel Laboratories involved in the study, or an immediate family member (partner, offspring, parents, siblings or sibling's offspring) of an employee involved in the study.
  • Any other condition or factor the investigator or his duly assigned representative believes may affect the skin response or the interpretation of the test results.
Both
18 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00964366
114545, C0000-408
No
Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
Stiefel, a GSK Company
GlaxoSmithKline
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP